Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor.
Cellular and/or serum components of polymorphonuclear leucocyte chemotaxis were assessed in 21 patients with rheumatoid arthritis. No difference in the chemotactic migration of control and patient cells in response to a number of chemotactic solutions could be detected (P = 0.38). Deficient generation of chemotactic activity in patient sera (P = 0.58) as compared to control sera (P = 0.014) after incubation of the sera with Escherichia coli lipopolysaccharide, resulted in a significant difference in the chemotactic activity of the control and rheumatoid serum preparations for polymorphonuclear leucocytes (P = 0.0012). This defect was associated with the presence of a serum inhibitor of chemotaxis, the potency of which was inversely correlated with the level of chemotactic activity generated in the rheumatoid sera (r = -0.941, P less than 0.001).
D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000503:physiopathology; D002630:Chemotactic Factors / Q000097:blood; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D004926:Escherichia coli; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D009504:Neutrophils / Q000502:physiology
D002630:Chemotactic Factors; D008070:Lipopolysaccharides